Skip to main content
Erschienen in: Obesity Surgery 3/2021

19.11.2020 | Original Contributions

Efficacy of Liraglutide to Prevent Weight Regain After Retrieval of an Adjustable Intra-gastric Balloon—a Case-Matched Study

verfasst von: Dilhana Badurdeen, Anna Carolina Hoff, Sergio Barrichello, Abdellah Hedjoudje, Mohamad I. Itani, Jad Farha, Shahem Abbarh, Atif Adam, Vikesh K. Singh, Saowanee Ngamruengphong, Andreas Oberbach, Mouen A. Khashab, Manoel Galvao Neto, Vivek Kumbhari

Erschienen in: Obesity Surgery | Ausgabe 3/2021

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Weight regain after balloon retrieval is a concern with all intra-gastric balloons (IGBs). The aim of this study was to evaluate the efficacy of liraglutide, a glucagon-like peptide-1 (GLP-1) agonist, to prevent weight regain following IGB retrieval.

Materials and Methods

This was a case-matched study of patients undergoing Spatz3 adjustable IGB (Spatz FGIA, Inc. NY, USA) at three outpatient clinics in Brazil between November 2015 and January 2019. Seventy-seven patients that opted to take liraglutide following IGB retrieval (IGB-L) were matched 1:1 to 198 patients that declined the medication—IGB-Alone (IGB-A). Propensity score adjustment was performed at the time of balloon retrieval on factors known to influence the choice of liraglutide. Weight and percent body fat (%BF) was measured at baseline and 9 months after IGB retrieval. % BF is defined as the total mass of fat divided by total body mass, multiplied by 100. The primary outcome was weight regain, and the secondary outcome was change in %BF 9 months after IGB retrieval.

Results

Propensity score matching yielded 53 matched pairs. Weight regain to the starting point was not observed in either group. There was significantly less weight regain in IGB-L compared to IGB-A, − 1.15 ± 0.94 kg versus − 0.66 ± 0.99 kg (p = 0.010) 9 months after balloon retrieval. Additionally, %BF decline in IGB-L was superior to IGB-A − 10.83 ± 1.50 versus − 7.94 ± 2.02 (p < 0.01). There was no difference in weight regain or decline in %BF based on liraglutide dose.

Conclusion

Liraglutide has an additive benefit with respect to efficacy and a reduction in body fat when commenced after IGB retrieval. Future randomized control studies will be needed to determine the optimal dose and duration of liraglutide to achieve superior outcomes.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Afshin A, Forouzanfar MH, Reitsma MB, et al. Health effects of overweight and obesity in 195 countries over 25 years. N Engl J Med. 2017;377(1):13–27.CrossRef Afshin A, Forouzanfar MH, Reitsma MB, et al. Health effects of overweight and obesity in 195 countries over 25 years. N Engl J Med. 2017;377(1):13–27.CrossRef
3.
Zurück zum Zitat Velapati SR, Shah M, Kuchkuntla AR, et al. Weight regain after bariatric surgery: prevalence, etiology, and treatment. Curr Nutr Rep. 2018;7(4):329–34.CrossRef Velapati SR, Shah M, Kuchkuntla AR, et al. Weight regain after bariatric surgery: prevalence, etiology, and treatment. Curr Nutr Rep. 2018;7(4):329–34.CrossRef
4.
Zurück zum Zitat Perugini RA, Mason R, Czerniach DR, et al. Predictors of complication and suboptimal weight loss after laparoscopic Roux-en-Y gastric bypass: a series of 188 patients. Arch Surg. 2003;138(5):541–6.CrossRef Perugini RA, Mason R, Czerniach DR, et al. Predictors of complication and suboptimal weight loss after laparoscopic Roux-en-Y gastric bypass: a series of 188 patients. Arch Surg. 2003;138(5):541–6.CrossRef
5.
Zurück zum Zitat Odom J, Zalesin KC, Washington TL, et al. Behavioral predictors of weight regain after bariatric surgery. Obes Surg. 2010;20(3):349–56.CrossRef Odom J, Zalesin KC, Washington TL, et al. Behavioral predictors of weight regain after bariatric surgery. Obes Surg. 2010;20(3):349–56.CrossRef
6.
Zurück zum Zitat Kushner RF, Sorensen KW. Prevention of weight regain following bariatric surgery. Curr Obes Rep. 2015;4(2):198–206.CrossRef Kushner RF, Sorensen KW. Prevention of weight regain following bariatric surgery. Curr Obes Rep. 2015;4(2):198–206.CrossRef
7.
Zurück zum Zitat Bakr AA, Fahmy MH, Elward AS, et al. Analysis of medium-term weight regain 5 years after laparoscopic sleeve gastrectomy. Obes Surg. 2019;29(11):3508–13.CrossRef Bakr AA, Fahmy MH, Elward AS, et al. Analysis of medium-term weight regain 5 years after laparoscopic sleeve gastrectomy. Obes Surg. 2019;29(11):3508–13.CrossRef
8.
Zurück zum Zitat Usuy E, Brooks J. Response rates with the Spatz3 adjustable balloon. Obes Surg. 2018;28(5):1271–6.CrossRef Usuy E, Brooks J. Response rates with the Spatz3 adjustable balloon. Obes Surg. 2018;28(5):1271–6.CrossRef
9.
Zurück zum Zitat Brooks J, Srivastava E, Mathus-Vliegen E. One-year adjustable intragastric balloons: results in 73 consecutive patients in the UK. Obes Surg. 2014;24(5):813–9.CrossRef Brooks J, Srivastava E, Mathus-Vliegen E. One-year adjustable intragastric balloons: results in 73 consecutive patients in the UK. Obes Surg. 2014;24(5):813–9.CrossRef
10.
Zurück zum Zitat Neto MG, Silva LB, Grecco E, et al. Brazilian Intragastric balloon consensus statement (BIBC): practical guidelines based on experience of over 40,000 cases. Surg Obes Relat Dis. 2018;14(2):151–9.CrossRef Neto MG, Silva LB, Grecco E, et al. Brazilian Intragastric balloon consensus statement (BIBC): practical guidelines based on experience of over 40,000 cases. Surg Obes Relat Dis. 2018;14(2):151–9.CrossRef
11.
Zurück zum Zitat Ponce J, Woodman G, Swain J, et al. The REDUCE pivotal trial: a prospective, randomized controlled pivotal trial of a dual intragastric balloon for the treatment of obesity. Surg Obes Relat Dis. 2015;11(4):874–81.CrossRef Ponce J, Woodman G, Swain J, et al. The REDUCE pivotal trial: a prospective, randomized controlled pivotal trial of a dual intragastric balloon for the treatment of obesity. Surg Obes Relat Dis. 2015;11(4):874–81.CrossRef
12.
Zurück zum Zitat Imaz I, Martínez-Cervell C, García-Álvarez EE, et al. Safety and effectiveness of the intragastric balloon for obesity. A meta-analysis. Obes Surg. 2008;18(7):841–6.CrossRef Imaz I, Martínez-Cervell C, García-Álvarez EE, et al. Safety and effectiveness of the intragastric balloon for obesity. A meta-analysis. Obes Surg. 2008;18(7):841–6.CrossRef
13.
Zurück zum Zitat Machytka E, Brooks J, Buzga M, et al. One year adjustable intragastric balloon: safety and efficacy of the Spatz3 adjustable balloons. F1000Res. 2014;3(203):203.CrossRef Machytka E, Brooks J, Buzga M, et al. One year adjustable intragastric balloon: safety and efficacy of the Spatz3 adjustable balloons. F1000Res. 2014;3(203):203.CrossRef
14.
Zurück zum Zitat Totté E, Hendrickx L, Pauwels M, et al. Weight reduction by means of intragastric device: experience with the bioenterics intragastric balloon. Obes Surg. 2001;11(4):519–23.CrossRef Totté E, Hendrickx L, Pauwels M, et al. Weight reduction by means of intragastric device: experience with the bioenterics intragastric balloon. Obes Surg. 2001;11(4):519–23.CrossRef
15.
Zurück zum Zitat Peker Y, Durak E, Ozgürbüz U. Intragastric balloon treatment for obesity: prospective single-center study findings. Obes Facts. 2010;3(2):105–8.CrossRef Peker Y, Durak E, Ozgürbüz U. Intragastric balloon treatment for obesity: prospective single-center study findings. Obes Facts. 2010;3(2):105–8.CrossRef
16.
Zurück zum Zitat Machytka E, Klvana P, Kornbluth A, et al. Adjustable intragastric balloons: a 12-month pilot trial in endoscopic weight loss management. Obes Surg. 2011;21(10):1499–507.CrossRef Machytka E, Klvana P, Kornbluth A, et al. Adjustable intragastric balloons: a 12-month pilot trial in endoscopic weight loss management. Obes Surg. 2011;21(10):1499–507.CrossRef
17.
Zurück zum Zitat Kotzampassi K, Grosomanidis V, Papakostas P, et al. 500 intragastric balloons: what happens 5 years thereafter? Obes Surg. 2012;22(6):896–903.CrossRef Kotzampassi K, Grosomanidis V, Papakostas P, et al. 500 intragastric balloons: what happens 5 years thereafter? Obes Surg. 2012;22(6):896–903.CrossRef
18.
Zurück zum Zitat Angrisani L, Lorenzo M, Borrelli V, et al. Is bariatric surgery necessary after intragastric balloon treatment? Obes Surg. 2006;16(9):1135–7.CrossRef Angrisani L, Lorenzo M, Borrelli V, et al. Is bariatric surgery necessary after intragastric balloon treatment? Obes Surg. 2006;16(9):1135–7.CrossRef
19.
Zurück zum Zitat Crea N, Pata G, Della Casa D, et al. Improvement of metabolic syndrome following intragastric balloon: 1 year follow-up analysis. Obes Surg. 2009;19(8):1084–8.CrossRef Crea N, Pata G, Della Casa D, et al. Improvement of metabolic syndrome following intragastric balloon: 1 year follow-up analysis. Obes Surg. 2009;19(8):1084–8.CrossRef
20.
Zurück zum Zitat Haddad AE, Rammal MO, Soweid A, et al. Intragastric balloon treatment of obesity: long-term results and patient satisfaction. Turk J Gastroenterol. 2019;30(5):461–6.CrossRef Haddad AE, Rammal MO, Soweid A, et al. Intragastric balloon treatment of obesity: long-term results and patient satisfaction. Turk J Gastroenterol. 2019;30(5):461–6.CrossRef
21.
Zurück zum Zitat Mosli MM, Elyas M. Does combining liraglutide with intragastric balloon insertion improve sustained weight reduction? Saudi J Gastroenterol. 2017;23(2):117–22.PubMedPubMedCentral Mosli MM, Elyas M. Does combining liraglutide with intragastric balloon insertion improve sustained weight reduction? Saudi J Gastroenterol. 2017;23(2):117–22.PubMedPubMedCentral
22.
Zurück zum Zitat Hoff AC, Fittipaldi-Fernandez RJ, Barrichello SA. Tu1917–Impacts of liraglutide use in weight maintenance after balloon retrieval: a 12-month follow up. Gastroenterology. 2019;156(6):S-1172–S-3.CrossRef Hoff AC, Fittipaldi-Fernandez RJ, Barrichello SA. Tu1917–Impacts of liraglutide use in weight maintenance after balloon retrieval: a 12-month follow up. Gastroenterology. 2019;156(6):S-1172–S-3.CrossRef
23.
Zurück zum Zitat Apovian CM, Aronne LJ, Bessesen DH, et al. Pharmacological management of obesity: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2015;100(2):342–62.CrossRef Apovian CM, Aronne LJ, Bessesen DH, et al. Pharmacological management of obesity: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2015;100(2):342–62.CrossRef
24.
Zurück zum Zitat Astrup A, Rössner S, Van Gaal L, et al. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet (London, England). 2009;374(9701):1606–16.CrossRef Astrup A, Rössner S, Van Gaal L, et al. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet (London, England). 2009;374(9701):1606–16.CrossRef
25.
Zurück zum Zitat Pi-Sunyer X, Astrup A, Fujioka K, et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med. 2015;373(1):11–22.CrossRef Pi-Sunyer X, Astrup A, Fujioka K, et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med. 2015;373(1):11–22.CrossRef
26.
Zurück zum Zitat Ling CH, de Craen AJ, Slagboom PE, et al. Accuracy of direct segmental multi-frequency bioimpedance analysis in the assessment of total body and segmental body composition in middle-aged adult population. Clin Nutr. 2011;30(5):610–5.CrossRef Ling CH, de Craen AJ, Slagboom PE, et al. Accuracy of direct segmental multi-frequency bioimpedance analysis in the assessment of total body and segmental body composition in middle-aged adult population. Clin Nutr. 2011;30(5):610–5.CrossRef
27.
Zurück zum Zitat Cotton PB, Eisen GM, Aabakken L, et al. A lexicon for endoscopic adverse events: report of an ASGE workshop. Gastrointest Endosc. 2010;71(3):446–54.CrossRef Cotton PB, Eisen GM, Aabakken L, et al. A lexicon for endoscopic adverse events: report of an ASGE workshop. Gastrointest Endosc. 2010;71(3):446–54.CrossRef
28.
Zurück zum Zitat Vargas EJ, Rizk M, Bazerbachi F, et al. Changes in gastric emptying with the Spatz3 adjustable intragastric balloon are associated with increased weight loss: a prospective study. Surg Obes Relat Dis. 2018;14(11):S118.CrossRef Vargas EJ, Rizk M, Bazerbachi F, et al. Changes in gastric emptying with the Spatz3 adjustable intragastric balloon are associated with increased weight loss: a prospective study. Surg Obes Relat Dis. 2018;14(11):S118.CrossRef
29.
Zurück zum Zitat Samsom M, Hauskens T, Mundt M. Gastric accommodation is influenced by the presence of an intragastric balloon. Gastroenterology. 2000;118(4):A621.CrossRef Samsom M, Hauskens T, Mundt M. Gastric accommodation is influenced by the presence of an intragastric balloon. Gastroenterology. 2000;118(4):A621.CrossRef
30.
Zurück zum Zitat Keith Jr CJ, Gullick AA, Feng K, et al. Predictive factors of weight regain following laparoscopic Roux-en-Y gastric bypass. Surg Endosc. 2018;32(5):2232–8.CrossRef Keith Jr CJ, Gullick AA, Feng K, et al. Predictive factors of weight regain following laparoscopic Roux-en-Y gastric bypass. Surg Endosc. 2018;32(5):2232–8.CrossRef
31.
Zurück zum Zitat Sander B, Arantes VN, Alberti L, et al. 550 long-term effect of intragastric balloon in the management of obesity. Gastrointest Endosc. 2017;85(5):AB83.CrossRef Sander B, Arantes VN, Alberti L, et al. 550 long-term effect of intragastric balloon in the management of obesity. Gastrointest Endosc. 2017;85(5):AB83.CrossRef
32.
Zurück zum Zitat Chapman CD, Benedict C, Brooks SJ, et al. Lifestyle determinants of the drive to eat: a meta-analysis. Am J Clin Nutr. 2012;96(3):492–7.CrossRef Chapman CD, Benedict C, Brooks SJ, et al. Lifestyle determinants of the drive to eat: a meta-analysis. Am J Clin Nutr. 2012;96(3):492–7.CrossRef
33.
Zurück zum Zitat Hall KD, Guo J. Obesity energetics: body weight regulation and the effects of diet composition. Gastroenterology. 2017;152(7):1718–27.e3.CrossRef Hall KD, Guo J. Obesity energetics: body weight regulation and the effects of diet composition. Gastroenterology. 2017;152(7):1718–27.e3.CrossRef
34.
Zurück zum Zitat Müller MJ, Enderle J, Bosy-Westphal A. Changes in energy expenditure with weight gain and weight loss in humans. Curr Obes Rep. 2016;5(4):413–23.CrossRef Müller MJ, Enderle J, Bosy-Westphal A. Changes in energy expenditure with weight gain and weight loss in humans. Curr Obes Rep. 2016;5(4):413–23.CrossRef
35.
Zurück zum Zitat Magro DO, Geloneze B, Delfini R, et al. Long-term weight regain after gastric bypass: a 5-year prospective study. Obes Surg. 2008;18(6):648–51.CrossRef Magro DO, Geloneze B, Delfini R, et al. Long-term weight regain after gastric bypass: a 5-year prospective study. Obes Surg. 2008;18(6):648–51.CrossRef
36.
Zurück zum Zitat Gómez V, Woodman G, Abu Dayyeh BK. Delayed gastric emptying as a proposed mechanism of action during intragastric balloon therapy: results of a prospective study. Obesity (Silver Spring). 2016;24(9):1849–53.CrossRef Gómez V, Woodman G, Abu Dayyeh BK. Delayed gastric emptying as a proposed mechanism of action during intragastric balloon therapy: results of a prospective study. Obesity (Silver Spring). 2016;24(9):1849–53.CrossRef
37.
Zurück zum Zitat Saxenda (liraglutide) [package insert] Plainsboro, NJ: Novo Nordisk Saxenda (liraglutide) [package insert] Plainsboro, NJ: Novo Nordisk
40.
Zurück zum Zitat Fittipaldi-Fernandez RJ, Hoff AC, Barrichello SA. Sa1982 intragastric balloon treatment in association with liraglutide: a novel approach in the excess weight treatment. Gastrointest Endosc. 2019;89(6):AB271.CrossRef Fittipaldi-Fernandez RJ, Hoff AC, Barrichello SA. Sa1982 intragastric balloon treatment in association with liraglutide: a novel approach in the excess weight treatment. Gastrointest Endosc. 2019;89(6):AB271.CrossRef
41.
Zurück zum Zitat Pajecki D, Halpern A, Cercato C, et al. Short-term use of liraglutide in the management of patients with weight regain after bariatric surgery. Rev Col Bras Cir. 2013;40(3):191–5.CrossRef Pajecki D, Halpern A, Cercato C, et al. Short-term use of liraglutide in the management of patients with weight regain after bariatric surgery. Rev Col Bras Cir. 2013;40(3):191–5.CrossRef
42.
Zurück zum Zitat Stanford FC, Alfaris N, Gomez G, et al. The utility of weight loss medications after bariatric surgery for weight regain or inadequate weight loss: a multi-center study. Surg Obes Relat Dis. 2017;13(3):491–500.CrossRef Stanford FC, Alfaris N, Gomez G, et al. The utility of weight loss medications after bariatric surgery for weight regain or inadequate weight loss: a multi-center study. Surg Obes Relat Dis. 2017;13(3):491–500.CrossRef
43.
Zurück zum Zitat Feng WH, Bi Y, Li P, et al. Effects of liraglutide, metformin and gliclazide on body composition in patients with both type 2 diabetes and non-alcoholic fatty liver disease: a randomized trial. J Diabetes Investig. 2019;10(2):399–407.CrossRef Feng WH, Bi Y, Li P, et al. Effects of liraglutide, metformin and gliclazide on body composition in patients with both type 2 diabetes and non-alcoholic fatty liver disease: a randomized trial. J Diabetes Investig. 2019;10(2):399–407.CrossRef
44.
Zurück zum Zitat le Roux CW, Astrup A, Fujioka K, et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. Lancet. 2017;389(10077):1399–409.CrossRef le Roux CW, Astrup A, Fujioka K, et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. Lancet. 2017;389(10077):1399–409.CrossRef
Metadaten
Titel
Efficacy of Liraglutide to Prevent Weight Regain After Retrieval of an Adjustable Intra-gastric Balloon—a Case-Matched Study
verfasst von
Dilhana Badurdeen
Anna Carolina Hoff
Sergio Barrichello
Abdellah Hedjoudje
Mohamad I. Itani
Jad Farha
Shahem Abbarh
Atif Adam
Vikesh K. Singh
Saowanee Ngamruengphong
Andreas Oberbach
Mouen A. Khashab
Manoel Galvao Neto
Vivek Kumbhari
Publikationsdatum
19.11.2020
Verlag
Springer US
Erschienen in
Obesity Surgery / Ausgabe 3/2021
Print ISSN: 0960-8923
Elektronische ISSN: 1708-0428
DOI
https://doi.org/10.1007/s11695-020-05117-8

Weitere Artikel der Ausgabe 3/2021

Obesity Surgery 3/2021 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.